| 臺大學術典藏 |
2022-09-15T05:42:25Z |
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study
|
Liu C.-H.; Sun H.-Y.; Peng C.-Y.; Hsieh S.-M.; Yang S.-S.; Kao W.-Y.; Shih Y.-L.; Lin C.-L.; Liu C.-J.; Sheng W.-H.; Lo Y.-C.; Liu W.-C.; Wu J.-H.; Su T.-H.; Tseng T.-C.; Chen P.-J.; CHIEN-CHING HUNG; Kao J.-H. |
| 臺大學術典藏 |
2022-09-09T04:21:34Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Liu C.-J.; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; Fang Y.-J.; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-09-09T04:21:27Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-09-09T04:21:16Z |
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study
|
Liu C.-H.; Sun H.-Y.; Peng C.-Y.; Hsieh S.-M.; Yang S.-S.; Kao W.-Y.; Shih Y.-L.; Lin C.-L.; Liu C.-J.; Sheng W.-H.; Lo Y.-C.; Liu W.-C.; Wu J.-H.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-08-19T00:20:50Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Cheng A.-L.; Chen P.-J.; Liu T.-W.; Chang C.-S.; Tien H.-F.; CHIUN HSU; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J. |
| 臺大學術典藏 |
2022-06-27T07:07:55Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU; Chang W.-C.; Kuo H.-P.; Yu C.-T.; Lin Z.-Z.; Kao W.-Y. |
| 臺大學術典藏 |
2022-06-10T06:11:17Z |
Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:15Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 臺大學術典藏 |
2022-04-29T08:09:50Z |
Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers
|
Kao W.-Y.; Yang S.-H.; Liu W.-J.; Yeh M.-Y.; Lin C.-L.; Liu C.-J.; Huang C.-J.; Lin S.-M.; Lee S.-D.; Chen P.-J.; MING-WHEI YU |
| 臺大學術典藏 |
2022-04-25T06:12:45Z |
Effects of growth temperature on gas exchange of Chamaecyparis formosensis and C. obtusa var. formosana seedlings occupying different ecological niches
|
Huang Y.-L;Kao W.-Y;Yeh T.-F;Chang S.-T.; Huang Y.-L; Kao W.-Y; Yeh T.-F; Chang S.-T.; TING-FENG YEH |
| 臺大學術典藏 |
2022-03-10T05:59:25Z |
High TSH level within normal range is associated with obesity, dyslipidemia, hypertension, inflammation, hypercoagulability, and the metabolic syndrome: A novel cardiometabolic marker
|
YI-CHENG CHANG; Hua S.-C.; Chang C.-H.; Kao W.-Y.; Lee H.-L.; Chuang L.-M.; Huang Y.-T.; Lai M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:45Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; YU-JEN FANG; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:43Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; YU-JEN FANG; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:42Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; YU-JEN FANG; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.‐Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:42Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Liu C.-J.; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; YU-JEN FANG; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:25Z |
Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers
|
Kao W.-Y.; Yang S.-H.; Liu W.-J.; Yeh M.-Y.; Lin C.-L.; CHUN-JEN LIU; Huang C.-J.; Lin S.-M.; Lee S.-D.; Chen P.-J.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; CHUN-JEN LIU; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:53Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; CHUN-JEN LIU; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; Fang Y.-J.; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2021-10-12T01:47:31Z |
High TSH level within normal range is associated with obesity, dyslipidemia, hypertension, inflammation, hypercoagulability, and the metabolic syndrome: A novel cardiometabolic marker
|
Chang Y.-C.; Hua S.-C.; Chang C.-H.; Kao W.-Y.; Lee H.-L.; LEE-MING CHUANG; Huang Y.-T.; Lai M.-S. |
| 臺大學術典藏 |
2021-09-04T05:16:42Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:25Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-01T02:02:29Z |
Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:25Z |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
|
ANN-LII CHENG; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. |
| 臺大學術典藏 |
2021-09-01T02:02:19Z |
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
|
Chao Y.; Yeh K.H.; Chang C.J.; Chen L.T.; Chao T.Y.; Wu M.F.; Chang C.S.; Chang J.Y.; Chung C.Y.; Kao W.Y.; Hsieh R.K.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:14Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. |
| 臺大學術典藏 |
2021-09-01T02:02:10Z |
An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer
|
Chao Y.; Li C.P.; Chao T.Y.; Su W.C.; Hsieh R.K.; Wu M.F.; Yeh K.H.; Kao W.Y.; Chen L.T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:40Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Hsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:42Z |
A phase i clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment John T Kung
|
Liu K.-J.; Chao T.-Y.; Chang J.-Y.; ANN-LII CHENG; Ch'Ang H.-J.; Kao W.-Y.; Wu Y.-C.; Yu W.-L.; Chung T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2021-08-11T03:46:54Z |
Combination of 13-cis retinoic acid and interferon-�\ in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.; ZHONG-ZHE LIN; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 臺大學術典藏 |
2021-07-28T06:46:58Z |
A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline
|
Hong R.-L.; CHING-HUNG LIN; Chao T.-Y.; Kao W.-Y.; Wang C.-H.; Hsieh R.K.; Hwang W.-S. |
| 臺大學術典藏 |
2021-07-26T10:04:11Z |
Effects of growth temperature on gas exchange of Chamaecyparis formosensis and C. obtusa var. formosana seedlings occupying different ecological niches
|
Huang Y.-L;Kao W.-Y;Yeh T.-F;Chang S.-T.; Huang Y.-L; Kao W.-Y; Yeh T.-F; Chang S.-T.; WEN-YUAN KAO |
| 臺大學術典藏 |
2021-07-26T10:04:05Z |
Novel serotonin-boosting effect of incense smoke from Kynam agarwood in mice: The involvement of multiple neuroactive pathways
|
Kao W.-Y;Hsiang C.-Y;Ho S.-C;Ho T.-Y;Lee K.-T.; Kao W.-Y; Hsiang C.-Y; Ho S.-C; Ho T.-Y; Lee K.-T.; KUNG-TA LEE |
| 臺大學術典藏 |
2021-07-26T09:44:13Z |
Effects of growth temperature on gas exchange of Chamaecyparis formosensis and C. obtusa var. formosana seedlings occupying different ecological niches
|
Huang Y.-L;Kao W.-Y;Yeh T.-F;Chang S.-T.; Huang Y.-L; Kao W.-Y; Yeh T.-F; Chang S.-T.; SHANG-TZEN CHANG |
| 臺大學術典藏 |
2021-07-03T03:35:40Z |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
|
Cheng A.-L.; Hsiung C.A.; Su I.-J.; PEI-JER CHEN; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. |
| 臺大學術典藏 |
2021-07-03T03:35:21Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:10Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Hsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:33:49Z |
Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers
|
Kao W.-Y.; Yang S.-H.; Liu W.-J.; Yeh M.-Y.; Lin C.-L.; Liu C.-J.; Huang C.-J.; Lin S.-M.; Lee S.-D.; PEI-JER CHEN; Yu M.-W. |
| 臺大學術典藏 |
2021-07-03T03:33:20Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:20Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
CHEN-HUA LIU; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:14Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
CHEN-HUA LIU; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?�Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T06:46:09Z |
A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline
|
Ruey-Long Hong;Lin C.-H.;Chao T.-Y.;Kao W.-Y.;Wang C.-H.;Hsieh R.K.;Hwang W.-S.; RUEY-LONG HONG; Lin C.-H.; Chao T.-Y.; Kao W.-Y.; Wang C.-H.; Hsieh R.K.; Hwang W.-S. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:53Z |
Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Kun-Huei Yeh;Wang C.-H.;Hsu C.-H.;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; KUN-HUEI YEH; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L. |
